Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer ...
Find similar stocks with Morningstar Investor.
A topnotch high-yield muni offering. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market cycle on a ...
Provided by Dow Jones Nov 13, 2026, 6:56:00 PM ...
There is no Morningstar’s Analysis data available.
A disciplined approach built to endure. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market cycle ...
Consistency backed by scale and skill. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market cycle on ...
Will PRWCX outperform in the future? Get our overall rating based on a fundamental assessment of the pillars below. The last time new investors could buy shares of T. Rowe Price Capital Appreciation, ...
More team changes coming in 2026. Our research team assigns Neutral ratings to strategies they’re not confident will outperform their Morningstar Category average over a market cycle on a ...
Provided by GlobeNewswire Nov 13, 2026, 5:15:00 PM ...
A strong option despite a recent cold streak. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results